Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
1 other identifier
interventional
N/A
1 country
4
Brief Summary
Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 21, 2002
CompletedFirst Posted
Study publicly available on registry
May 22, 2002
CompletedAugust 14, 2009
August 1, 2009
May 21, 2002
August 13, 2009
Conditions
Keywords
Interventions
Eligibility Criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (4)
Research Center
Detroit, Michigan, 48201, United States
Research Center
New Brunswick, New Jersey, 08901, United States
Research Center
Nashville, Tennessee, 37232, United States
Research Center
Marshfield, Wisconsin, 54449, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 21, 2002
First Posted
May 22, 2002
Last Updated
August 14, 2009
Record last verified: 2009-08